
Metsera CEO Whit Bernard joins Venrock's Nimish Shah to discuss how the company's ultra-long acting GLP-1 program helped position it as a strategic standout in the obesity market. The conversation covers the bidding war between major pharma players, lessons in first-principles company building, and why the next decade of biotech could reward high-volume, accessible innovation.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Free AI-powered recaps of Running Through Walls and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.